---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incretin-based therapies"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incretin-based therapies. Topics: FDA-approved indication and dosage: semaglutide 2.4 mg injection for noncirrhotic MASH; ESSENCE part 1 primary end points: planned interim analysis of the first 800 patients at week 72; AASLD update to the practice guidance on semaglutide: indication, patient selection, and cirrhosis; AASLD update to the practice guidance on semaglutide: combination with resmetirom; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/incretin-based-therapies"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incretin-based therapies

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Incretin-based Therapies

<a id="topic-2.2.2.1.3-1"></a>

### FDA-approved indication and dosage: semaglutide 2.4 mg injection for noncirrhotic MASH

> “WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:”
> “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis”
> “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.2.2.1.3-2"></a>

### ESSENCE part 1 primary end points: planned interim analysis of the first 800 patients at week 72

> “In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1).”
> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001).”
> “A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”
> “Gastrointestinal adverse events were more common in the semaglutide group.”

Source: [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258)

<a id="topic-2.2.2.1.3-3"></a>

### AASLD update to the practice guidance on semaglutide: indication, patient selection, and cirrhosis

> “This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction–associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide.”
> “Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients.”
> “Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.3-4"></a>

### AASLD update to the practice guidance on semaglutide: combination with resmetirom

> “Combination use with resmetirom at the dose of 2.4 mg/week has not been studied.”
> “However, semaglutide and resmetirom have not been studied as a combination therapy for MASH, nor have they been compared for relative efficacy.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.3-5"></a>

### ADA Standards of Care recommendations 4.26 and 4.27a: GLP-1 RA and dual GIP and GLP-1 RA in adults with type 2 diabetes and MASLD

> “In adults with type 2 diabetes, MASLD, and overweight or obesity, consider using a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with demonstrated benefits in MASH A or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with potential benefits in MASH B for the treatment of obesity as an adjunctive therapy to lifestyle interventions for weight loss.”
> “In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.”
> “Semaglutide is currently the only glucose-lowering or obesity medication that is FDA approved for the treatment of MASH.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.3-6"></a>

### EASL-EASD-EASO guideline recommendations on GLP-1 receptor agonists, issued while the semaglutide phase 3 trial was ongoing

> “In the absence of a formal demonstration of histological improvement in large, well conducted, phase III trials, glucagon-like peptide 1 receptor agonists (GLP1RA) cannot currently be recommended as MASH-targeted therapies (LoE 5, strong recommendation, strong consensus).”
> “GLP1RAs are safe to use in MASH (including compensated cirrhosis) and should be used for their respective indications, namely type 2 diabetes and obesity, as their use improves cardiometabolic outcomes (LoE 2, strong recommendation, strong consensus).”
> “In case of substantial weight loss induced by GLP1RAs, a hepatic histological benefit could be expected, although this has not been extensively documented so far (LoE 2, strong consensus).”
> “A large registrational, phase III study with semaglutide is ongoing.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.3-7"></a>

### AASLD practice guidance statement on semaglutide for its approved indications, issued before any GLP-1 RA was approved for NASH

> “Although several GLP-1RAs are approved for treatment of T2DM, none has been approved for treatment of NASH.”
> “Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH as it confers a cardiovascular benefit and improves NASH”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.3-8"></a>

### Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed

> “We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.”
> “Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.”
> “The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).”
> “The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).”
> “Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.”

Source: [Loomba et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38856224/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
